

1 **Advanced Echocardiographic Assessment in Transthyretin Amyloidosis:**
2 **Early Phenotype Markers in Mutation Carriers**

3 Lorena Squassante Capeline ^{1*}, Frederico José Neves Mancuso ^{1,2}, Gardênia
4 Silva Lobo Oishi ¹, Marly Uellendahl ¹, Fernando Naylor ³, Acary Souza Bulle
5 Oliveira ³, Valdir Ambrósio Moises ^{1,2*}.

6 ¹ Universidade Federal de São Paulo - Escola Paulista de Medicina, Disciplina
7 de Cardiologia, Setor de Ecocardiografia, São Paulo, São Paulo, Brazil.

8 ² Universidade Federal de São Paulo - Escola Paulista de Medicina, Disciplina
9 de Emergência e Medicina Baseada em Evidências, São Paulo, São Paulo,
10 Brazil.

11 ³ Universidade Federal de São Paulo, - Escola Paulista de Medicina, São Paulo,
12 Brazil. Doenças Neuromusculares, Disciplina de Neurologia Clínica,
13 Departamento de Neurologia e Neurocirurgia.

14 The work was performed at the Universidade Federal de São Paulo - Escola
15 Paulista de Medicina, São Paulo, São Paulo, Brazil.

16 Corresponding author: Tel.: +1 403 807 6486. E-mail: capeline@unifesp.br;
17 vmoises@unifesp.br

18

19 **Abstract**

20 **Background:** Transthyretin cardiac amyloidosis (ATTR-CA) is a life-threatening
21 heart condition due to mutations in the transthyretin (TTR) gene. This study aimed
22 to investigate ventricular global longitudinal strain (GLS) and global
23 circumferential strain (GCS) alongside traditional echocardiographic measures in
24 TTR carries with preserved ejection fraction (EF).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Methods:** Individuals with a family history of ATTR-CA, positive genetic testing
2 for TTR, no clinical cardiac involvement and preserved EF were matched with
3 healthy controls.

4 **Results:** Sixty-five patients were included: 31 TTR+ and 34 controls. No
5 significant differences in chamber dimensions or EF were observed between
6 groups. However, septal velocities were markedly lower in TTR+ than controls (9
7 [7;12] cm/s vs. 12 [10;13] cm/s, $p=0.003$). Additionally, both GCS and GLS were
8 significantly reduced in the TTR+ group compared to controls ($-21 \pm 4\%$ vs. -28
9 $\pm 4\%$, $p<0.001$ and $-19 \pm 3\%$ vs. $-25 \pm 2\%$, $p<0.001$, respectively). Furthermore,
10 right ventricular strain showed a similar trend, being lower in the TTR+ group
11 compared to controls ($-18 \pm 4\%$ vs. $-25 \pm 5\%$, $p<0.005$). Logistic regression
12 analysis identified GLS (OR = 2.46; 95% CI 1.30-4.62) and E/e' mean ratio (OR
13 = 2.04; 95% CI 1.09-3.91) as independent predictors of positive genetic testing
14 for TTR.

15 **Conclusion:** Asymptomatic individuals with a family history of ATTR-CA and
16 positive genetic testing for TTR, despite preserved EF, exhibit lower GLS and
17 GCS compared to controls. GLS and the E/e' ratio were identified as independent
18 predictors of positive genetic testing for TTR.

19

- 1 **Keywords:** cardiac amyloidosis; echocardiography; speckle-tracking; strain;
- 2 cardiomyopathies; hereditary ATTR amyloidosis.

1 **Introduction**

2 Hereditary transthyretin amyloidosis (ATTRv) represents a complex group
3 of autosomal dominant disorders characterized by the extracellular deposition of
4 amyloid fibrils derived from misfolded transthyretin (TTR). This condition is
5 associated with over 130 different mutations in the TTR gene, resulting in
6 significant variability in genotype-phenotype expression. Recent advancements
7 in treatment underscore the critical need for a standardized approach to patient
8 management, particularly focusing on accurate disease diagnosis and timely
9 intervention strategies ¹⁻⁴.

10 The timing and criteria for offering genetic testing to at-risk family members
11 remain uncertain and require consideration of multiple factors including the
12 specific mutation, penetrance, age of onset, and severity of disease in affected
13 relatives. Early identification of pathogenic ATTRv enables proactive screening
14 of asymptomatic gene carriers, facilitating prompt diagnosis and initiation of
15 disease-modifying therapies aimed at improving clinical outcomes ⁵.

16 Cardiac amyloidosis (CA), a notable cardiac manifestation of ATTRv, is
17 characterized by the infiltration of amyloid deposits within the myocardium,
18 leading to restrictive cardiomyopathy and significant implications for prognosis
19 and therapeutic decisions ⁶⁻⁸. The severity of CA is typically evaluated based on
20 parameters such as ventricular wall thickness, systolic, and diastolic function ⁸.
21 While diagnostic strategies for symptomatic CA are well-established, approaches
22 for detecting subclinical conditions remain limited ³. Given the nonspecific clinical
23 presentation, a high index of suspicion is crucial for accurate diagnosis, often
24 relying on non-invasive imaging techniques including echocardiography,
25 cardiovascular magnetic resonance, and cardiac scintigraphy ⁶. Moreover, with

1 specific treatments available, timely diagnosis of cardiac amyloidosis is crucial
2 than ever.

3 Contemporary echocardiographic methods, particularly strain and strain
4 rate analysis, have emerged as effective screening tools for detecting early
5 stages of CA. Two-dimensional speckle tracking echocardiography measures
6 myocardial deformation and has shown promise in distinguishing CA from other
7 cardiovascular conditions⁹. Unlike traditional measures such as ejection fraction
8 or shortening fraction, which may remain preserved until late disease stages,
9 speckle tracking echocardiography offers sensitivity to detect subtle myocardial
10 abnormalities early in the disease process⁹.

11 The aim of this study was to evaluate echocardiographic and myocardial
12 deformation alterations in carriers of the transthyretin variant with preserved
13 ejection fraction and a positive family history for transthyretin amyloid
14 cardiomyopathy. Additionally, the study seeks to identify clinical and
15 echocardiographic variables that predict the genetic diagnosis of ATTRv in this
16 population.

17 **Methods**

18 This cross-sectional study recruited individuals with a known family history
19 of ATTR-CA and positive genetic testing for TTR variant between January 2018
20 and December 2019 at a single tertiary center. Inclusion criteria comprised the
21 absence of clinical cardiac involvement and preserved ejection fraction. A control
22 group, matched for age and sex, was selected from healthy individuals without a
23 family history of ATTR-CA.

24 None of the participants exhibited symptoms such as dyspnea,
25 palpitations, syncope, arrhythmias, edema, or signs of cardiac disease upon

1 physical examination. These individuals were defined as asymptomatic
2 transthyretin variant carriers (TTR+) from a cardiovascular standpoint. All
3 participants underwent transthoracic 2-dimensional echocardiography (TTE)
4 confirming preserved ejection fraction at the time of enrollment.

5 Exclusion criteria included patients with a cardiac rhythm other than sinus
6 rhythm or electrocardiographic evidence of bundle branch block, uncontrolled
7 systemic arterial hypertension, primary valvular disease, congenital heart
8 disease, history of myocardial revascularization surgery, known coronary artery
9 disease, inadequate TTE images for strain analysis, or a history of previous
10 diseases affecting other organs that could potentially influence cardiac function.

11 All patients provided written informed consent to participate in the study,
12 which adhered to the principles of the Declaration of Helsinki and was approved
13 by the Institutional Research Ethics Committee.

14 **Clinical evaluation**

15 Cardiological evaluation was conducted concurrent with TTE
16 examinations. A comprehensive physical examination was performed, followed
17 by standard electrocardiography and TTE. Laboratory analyses were not
18 conducted specifically for the study.

19 **Genetic analysis**

20 Prior to study inclusion, all patients underwent genetic analysis as per
21 institutional protocol, conducted only after obtaining patient consent. Genetic
22 testing involved sequencing genes associated with neuropathies. Variant
23 classification followed the guidelines of the American College of Medical Genetics
24 ¹⁰.

25 **Echocardiography**

1 TTE examinations were conducted using a high-quality echocardiographic
2 system (CX 50, Philips Medical Systems, Andover, MA, USA) equipped with a 1
3 to 5 MHz transducer (S5-1). Patients were in the left lateral decubitus position for
4 the examination. Measurements were performed in accordance with current
5 guidelines from the European Association of Cardiovascular Imaging and
6 American Society of Echocardiography ¹¹.

7 Left ventricular (LV) measurements included assessment of LV
8 interventricular septum thickness (IVSd) and posterior wall thickness (PWd) at
9 end-diastole, as well as internal diastolic and systolic diameters. LV mass, LV
10 mass index, and relative wall thickness were calculated and applied to classify
11 LV geometry according to established guidelines. Systolic function was evaluated
12 using LV ejection fraction determined by the biplane Simpson's method ¹¹.

13 LV diastolic function was assessed using several parameters: mitral valve
14 inflow early (E) and late (A) diastolic velocities, E/A ratio, and deceleration time.
15 Additionally, tissue Doppler imaging measured early diastolic velocities of the
16 medial and lateral mitral annulus (e'), averaged to calculate mean E/e' in
17 accordance with established guidelines. Left atrial (LA) volume index and
18 maximum systolic velocity of tricuspid regurgitation, if available, were also utilized
19 to analyze diastolic function ¹².

20 LA volume was measured using the biplane area-length method and
21 indexed to body surface area to calculate the LA volume index. Right ventricular
22 (RV) size was assessed by diastolic diameter, and right atrial size by systolic
23 volume, both from the apical 4-chamber view, following recommended protocols
24 ¹¹.

1 To assess LV and RV systolic strain, all imaging acquisitions were digitally
2 recorded over five consecutive cardiac cycles and stored in raw format. Analysis
3 of recorded images was conducted by a single experienced echocardiographer
4 blinded to subject conditions using speckle-tracking method estimated by a
5 commercially available software validated for this purpose (QLAB Version 10.5;
6 Philips Medical Systems, Andover, MA, USA) ¹¹. The end-diastole was
7 considered as the first frame when the mitral valve was closed, and end-systole
8 was defined when the aortic valve was closed ¹³. The software traced speckles
9 along the endocardial and epicardial borders throughout the cardiac cycle, and
10 the region of interest was adjusted to encompass the entire myocardium ¹⁴.

11 LV longitudinal strain (LS) was assessed from the three apical long-axis
12 views (4-, 2-, and 3-chamber views), while circumferential strain (CS) was
13 evaluated from three short-axis views (base, mid, and apex). Global longitudinal
14 strain (GLS) and global circumferential strain (GCS) values were derived by
15 averaging LS and CS values, respectively, from all tracked LV segments ¹⁴. In
16 cases where tracking was challenging or segments were excluded due to
17 insufficient quality, GLS and GCS were recalculated using the remaining
18 segments to ensure consistency and reliability across analyses ¹⁴.

19 RV longitudinal strain was assessed using the apical four-chamber view
20 focused on the RV. Segmental strain values were obtained for distinct RV
21 segments (free wall and septum) based on tracked myocardial segments. Global
22 RV longitudinal strain (RVGLS) was derived by averaging segmental strain
23 values ¹⁵.

24 Established LV strain-derived variables were calculated: septal peak LS
25 apical to basal segment ratio (SAB) using 4-chamber view values; relative apical

1 sparing of GLS ratio (RELAPS), the average apical segments peak LS divided by
2 average basal and mid segments peak LS from all three apical views^{9,16,17}.
3 Published cut-offs for detecting CA are >2.1 for SAB, >1 for RELAPS^{9,16,17}.

4 **Statistical Analysis**

5 Data were analyzed using SPSS software (IBM Corporation, version 18,
6 New Orchard Road Armonk, NY). Continuous variables were expressed as mean
7 \pm standard deviation or median [interquartile range] and compared using
8 Student's t-test or Mann-Whitney test, as appropriate. Categorical variables were
9 compared using the chi-square test. Fisher's exact test was applied to analyze
10 categorical variables, and the likelihood ratio test was used to compare
11 distribution fits.

12 Univariate analysis encompassed clinical and echocardiographic
13 variables, with variables showing statistical significance (p -value < 0.10) included
14 in the multiple logistic regression model. A stepwise variable selection procedure
15 was employed to determine independent predictors of positive genetic study for
16 TTR. Receiver operating characteristic curves (ROC) were constructed to assess
17 predictive accuracy, with calculation of the area under the curve (AUC). Optimal
18 cut-off values were determined using the Youden index derived from ROC
19 curves. P -value <0.05 was considered statistically significant.

20 Intra and interobserver variabilities of GLS were assessed using the Bland-
21 Altman method in a subset of 10 randomly selected patients, 60 days after initial
22 assessment, with examiners blinded to previous results and each other's
23 assessments. The analysis included determination of bias and limits of
24 agreement to ensure reliability and consistency of measurements.

25

1 **Results**

2 Out of an initial enrollment of 36 individuals with TTR+, five were excluded
3 from the study: one due to atrial fibrillation, one with unstable angina diagnosed
4 during consultation, one with decompensated hypertension without specific
5 therapy, and two who had undergone liver transplants. Therefore, a total of 31
6 patients were eligible and enrolled (Figure 1). Controls consisted of 34
7 asymptomatic individuals without neurological disease, and with normal
8 laboratory and noninvasive cardiac test results. Comprehensive details of all 65
9 subjects included in the study are presented in Table 1.

10 There were no significant differences between the groups in terms of sex, age,
11 anthropometric measurements, obesity prevalence, blood pressure levels, or the
12 prevalence of arterial hypertension. Among the 31 patients with TTR+, 14
13 (45.2%) exhibited extracardiac symptoms during their cardiological assessment.
14 Specifically, polyneuropathy was observed in nine (29%) individuals, intestinal
15 symptoms in three (9.6%), and carpal tunnel syndrome and dysautonomia in one
16 (3.2%) individual each (Table 1).

17 **Genetic Characteristics**

18 Among the 31 carriers of the TTR variant with preserved ejection fraction
19 and a positive family history for ATTR-CA, the Val50Met variant was identified in
20 23 patients (74.1%). The Ile127Val variant was detected in four patients (13%),
21 while the Glu109Lys variant was found in two patients (6.5%). Additionally, the
22 Val142Ile and Ala117Ser variants each occurred in one case (3.2%).

23 **Echocardiographic parameters**

24 The main echocardiographic findings are summarized in Table 2. All
25 individuals with TTR+ had LV internal diameters within the normal range based

1 on reference values. However, individuals with TTR+ exhibited significantly
2 greater IVSd and PWd compared to controls (Table 2). Among the 31 TTR+
3 individuals, nine women had an IVSd greater than 9 mm, while five men had a
4 IVSd greater than 10 mm; additionally, five women had a PWd greater than 9
5 mm, and four men had an PWd greater than 10 mm. LV mass, LV mass indexed,
6 and LV relative wall thickness were significantly higher in the TTR+ group
7 compared to controls; alterations in LV geometric pattern were also more frequent
8 in the TTR+ group than in controls ($p < 0.001$) (Table 2). Among TTR+ individuals,
9 LV concentric remodeling occurred in eight (four men and four women), LV
10 concentric hypertrophy was observed in four (one man and three women), and
11 LV eccentric hypertrophy in one individual. In the control group, only two
12 individuals had LV concentric remodeling (Table 2).

13 LV ejection fraction did not differ significantly between the groups. Among
14 the parameters assessed for LV diastolic function, the septal and lateral e' waves
15 and E/A ratio were significantly lower in TTR+ individuals compared to controls,
16 although these values remained within the normal range (Table 2). The E/e' ratio
17 was significantly higher in the TTR+ group compared to controls.

18 Considering the majority of individuals had normal LV geometry, initial
19 guideline-based analysis indicated normal diastolic function in the control group,
20 with two individuals in the TTR+ group showing indeterminate diastolic function;
21 however, this difference was not statistically significant. When considering only
22 individuals with altered LV geometry, there were significantly more cases of
23 altered diastolic function in the TTR+ group (13 out of 31 individuals) compared
24 to controls (two out of 34 individuals) ($p < 0.007$). Among TTR+ individuals, 12

1 had type I diastolic dysfunction and one had type III. In the control group, both
2 individuals exhibited type I dysfunction (Table 2).

3 **Myocardial deformation**

4 GCS was markedly reduced in TTR+ individuals compared to controls,
5 measuring $-21 \pm 4\%$ versus $-28 \pm 4\%$, respectively ($p < 0.001$) (Table 3). In TTR+
6 group, four individuals exhibited GCS values below -18% , whereas in the control
7 group, only one individual had a GCS of -18% .

8 GLS was also significantly lower in TTR+ individuals compared to controls,
9 $-19 \pm 3\%$ versus $-25 \pm 2\%$, respectively ($p < 0.001$). Specifically, eight cases in
10 the TTR+ group and one in the control group had GLS values less than -18% ;
11 likewise, five cases in the TTR+ group had GLS values less than -16% .

12 Additionally, CS and LS values at basal, mid, and apical regions were
13 notably diminished in the TTR+ group compared to the Control group (Figure 2).
14 When comparing CS and LS values among basal, mid, and apical regions within
15 the same group, significant differences were observed. In the TTR+ group, CS
16 increased significantly from the basal region ($-18 \pm 4\%$) to the mid region ($-20 \pm$
17 4%) with a p-value of 0.002. The apical region had the highest CS at $-24 \pm 6\%$,
18 significantly different from both the basal and mid regions ($p < 0.001$). For LS, the
19 apical region showed higher values at $-23 \pm 4\%$ compared to the basal ($-17 \pm 3\%$)
20 and mid ($-18 \pm 3\%$) regions, with significant differences between apical and both
21 basal and mid ($p < 0.001$). In the Control group, CS increased from the basal
22 region ($-26 \pm 5\%$) to the mid region ($-27 \pm 5\%$), but this difference was not
23 significant ($p = 0.094$). The apical region had the highest CS at $-31 \pm 6\%$,
24 significantly different from both the basal and mid regions ($p < 0.001$). For LS,
25 values increased from basal ($-22 \pm 3\%$) to mid ($-24 \pm 3\%$), but this difference was

1 not significant ($p = 0.02$). The apical LS was higher at $-27 \pm 4\%$ compared to
2 basal and mid regions, with significant differences ($p < 0.001$).

3 RVGLS was assessed in eleven TTR+ individuals and eleven controls
4 (Table 3). RVGLS was significantly lower in the TTR+ group compared to the
5 control group ($-18 \pm 4\%$ versus $-25 \pm 5\%$). A similar pattern was observed in the
6 assessment of RV free wall GLS, with values of $-18 \pm 4\%$ in the TTR+ group
7 versus $-24 \pm 4\%$ in the control group.

8 In the TTR+ group, RELAPS was significantly elevated at 0.66 ± 0.08
9 compared to 0.58 ± 0.08 in the control group ($p < 0.001$), and the SAB index was
10 significantly elevated at 1.7 ± 0.3 compared to 1.4 ± 0.3 in the control group, with
11 a p-value less than 0.001 (Table 3).

12 The comparison of TTR+ individuals with and without extracardiac
13 symptoms no significant differences in GCS and GLS values were observed.
14 Specifically, GCS was $-21 \pm 3\%$ in asymptomatic individuals and $-20 \pm 3\%$ in
15 symptomatic individuals ($p = 0.510$). Similarly, GLS was $-20 \pm 3\%$ in
16 asymptomatic individuals and $-19 \pm 2\%$ in symptomatic individuals ($p = 0.322$).

17 ROC analysis identified an optimal LV GLS cutoff of -21.5% to distinguish
18 TTR+ individuals from controls, achieving a sensitivity of 87.1% and specificity of
19 91.2% (AUC = 0.890, 95% CI: 1.31 to 4.62, $p < 0.005$). Additionally, E/e' ratio of
20 6.5 demonstrated a sensitivity of 80.6% and specificity of 64.7% for the same
21 discrimination (AUC = 0.890, 95% CI: 1.31 to 4.62, $p < 0.005$) (Figure 3).

22 **Reproducibility**

23 The study demonstrated strong correlations and high reproducibility with
24 minimal bias. Interobserver variability had a bias of 0.235 and limits of agreement

1 (± 1.96 SD) from -3.97 to 4.17 ($p = 0.882$), while intra-observer variability had a
2 bias of 0.278 with limits of agreement from -2.62 to 2.42 ($p = 0.811$).

3 **Discussion**

4 This study provides compelling evidence that transthyretin variant carriers
5 exhibit impaired myocardial deformation despite having preserved ejection
6 fraction. Notably, our findings highlight a critical gap in the literature, as no
7 previous study has specifically emphasized the characteristics of carriers in this
8 context. Prior research has typically compared LV deformation in patients with
9 ATTRv against those with conditions such as aortic stenosis, hypertrophic
10 cardiomyopathy, or advanced-stage cardiac amyloidosis^{3,16,17}. Our study
11 uniquely addresses this oversight by concentrating on transthyretin variant
12 carriers, offering new insights into their myocardial deformation profile.

13 While myocardial biopsy remains the gold standard for definitively
14 diagnosing ATTR-CA, distinguishing it from other causes of increased myocardial
15 thickness in early stages presents ongoing clinical challenges^{1,18}. These findings
16 emphasize the importance of heightened awareness and early detection
17 strategies to improve outcomes for individuals with genetic predispositions to
18 cardiac amyloidosis.

19 In this study, both groups showed comparable variables, except for the
20 presence of extracardiac symptoms observed in some TTR+ individuals. The
21 genetic variants identified in our study align with findings in the literature,
22 indicating higher prevalence among American and Portuguese ethnicities¹⁹. This
23 underscores the diverse distribution of genetic variants associated with ATTR
24 and highlights the importance of considering ethnic variability in genetic studies
25 of this condition.

1 Among the 31 TTR+, 21 demonstrated alterations in myocardial thickness
2 and LV geometric patterns despite the absence of cardiovascular symptoms.
3 Specifically, five individuals exhibited LV hypertrophy, with four displaying
4 predominantly concentric hypertrophy and one showing eccentric hypertrophy.
5 Additionally, eight individuals showed minimal septal thickness increase, while
6 another eight exhibited concentric remodeling. A previous study underscored
7 increased LV mass and functional myocardial impairment in advanced ATTR-CA,
8 even with preserved LV ejection fraction ¹⁶. Early stages may mimic hypertensive
9 heart disease or other myocardial disorders. However, among TTR+ patients,
10 only two had hypertension, suggesting early ATTR-CA manifestations, such as
11 increased myocardial thickness and higher LV geometric alterations, may occur
12 independently of hypertensive. Amyloid deposition in ATTR-CA often targets the
13 interventricular septum, which may explain these findings ^{9,16,20}.

14 All TTR+ in this study exhibited normal LV ejection fraction. According to
15 diastolic function guidelines, assessing diastolic function in individuals with
16 normal systolic function includes evaluating septal or lateral e' waves, E/e' ratio,
17 LA volume index, and tricuspid regurgitation velocity ¹². None of the participants
18 met the criteria for diastolic dysfunction by this assessment, with diastolic function
19 being indeterminate in two individuals. Nevertheless, given the potential for
20 myocardial disease in these individuals, a secondary analysis commonly used in
21 patients with heart disease or systolic dysfunction revealed a higher prevalence
22 of diastolic dysfunction among TTR+ compared to controls: 12 individuals
23 exhibited type I diastolic dysfunction, typically asymptomatic with normal LA
24 pressure, while one displayed type III dysfunction, indicating elevated LA
25 pressure. Previous research has shown that early-stage ATTR-CA involves

1 myocardial amyloid deposition, leading to myocardial remodeling and fibrosis that
2 can impair diastolic relaxation ⁷. In this study, this pattern was observed in 12 out
3 of 31 TTR+. Diastolic filling parameters are known to carry prognostic significance
4 in ATTR-CA, with increased amyloid infiltration potentially causing a restrictive
5 pattern of LV filling ^{2,7,17}. The data from this study suggest that reductions in strain
6 may occur early in the disease among carriers of the ATTRv. These individuals
7 exhibited significantly lower values of RV strain, LV GCS and GLS compared to
8 controls. Similar findings were observed when comparing each LV regions
9 between TTR+ and control. Rapezzi et al. have described increased myocardial
10 thickness, altered diastolic function, and pericardial effusion as common cardiac
11 changes in advanced stages of ATTR-CA, complicating treatment and potentially
12 reducing survival ⁸.

13 In both study groups, LS and CS values progressively increased from the
14 basal to the apical regions. However, values in each region were significantly
15 lower in TTR+ compared to controls. RELAPS and SAB indices also differed
16 between groups, suggesting potentially greater involvement of the mid and basal
17 LV region in TTR+. This strain distribution in TTR+ individuals mirrors patterns
18 described by Phelan et al. in advanced stages of ATTR-CA ⁹. These authors
19 suggested that lower values of the basal and mid regions of the LV may result
20 from more intense amyloid deposition in these areas. Importantly, Phelan et al.
21 compared patients with ATTR-CA to those with hypertrophic cardiomyopathy and
22 aortic stenosis, rather than to a control group without apparent myocardial
23 disease, as in the present study ⁹. Cotella et al. in a recent publication including
24 large number of patients highlight that the apical sparing does not have a high
25 specificity for diagnosing cardiac amyloidosis ²¹. However, our study revealed

1 that these TTR+ patients show early differences of myocardial deformation
2 compared to controls with some regional left ventricular differences. This earlier
3 stage of cardiac involvement underscores the importance of assessing not only
4 the apical sparing pattern but also other echocardiographic variables, including
5 parameters of the diastolic function of the left ventricle. These analyses can
6 identify more subtle forms of myocardial changes in TTR+ carriers, facilitating
7 early diagnosis and contributing to the prognosis of these individuals.

8 Furthermore, there were no significant differences in LV CS and LS values
9 between TTR+ individuals with or without extracardiac symptoms, suggesting
10 that neurological symptoms may not predict LV strain alterations.

11 RV strain, whether including the interventricular septum or not, behaved
12 similarly to LV strain. In this study, four individuals in the TTR+ group had RV
13 strain values below -16%, considered abnormal. Histopathological studies have
14 shown a predilection for amyloid fibril deposition in the basal region of the
15 interventricular septum^{22,23}. This raises questions about including or excluding
16 the septum in RV strain analysis, with some arguing that including the septum
17 could complicate RV strain analysis and advocating for analyzing only the RV
18 free wall²⁴. In this study, RV GLS did not show significant difference regardless
19 of whether the septum was included or not.

20 Several variables in this study were significantly linked to a TTR+ genetic
21 test. However, logistic regression identified only GLS (OR = 2.46), and E/e' ratio
22 (OR = 2.07) as positively related to a TTR+ genetic test. $GLS \leq -21.5\%$
23 distinguished TTR+ patients from the control group with a sensitivity of 87.1%
24 and specificity of 91.2%. Similarly, $E/e' \text{ ratio} \geq 6.5$ had a sensitivity of 80.6% and
25 specificity of 64.7%. Chuy et al. demonstrated that GLS and E/e' ratio are

1 associated with overall survival in patients studied, providing incremental
2 prognostic value in advanced stages of the disease ²⁵.

3 The diagnostic challenge of ATTR-CA is compounded by the low
4 penetrance of the genetic variant and subtle multi-organ involvement, equally
5 amyloid fibril deposition progressively impacts tissues, with cardiac complications
6 being a major cause of mortality ²⁶. Therefore, early detection of cardiac
7 involvement is critical for timely intervention and improved patient outcomes. The
8 greatest clinical utility of our study is that it identified an early possible phenotypic
9 diagnosis and may assist in the treatment effort to delay the clinical course of the
10 disease.

11 **Limitations**

12 There are some limitations to consider in this study. Firstly, it was a cross-
13 sectional observational study conducted at a single tertiary referral center,
14 involving a relatively small cohort of patients at various stages of polyneuropathy
15 manifestation. However, given the low prevalence of confirmed cardiac
16 amyloidosis in the general population, the number of participants in this study
17 compares favorably with previously published research ^{3,16,17}.

18 Furthermore, the strain analysis was conducted using equipment from a
19 single supplier. Therefore, the findings may not be applicable to other
20 commercially available strain systems across all vendors, although this limitation
21 has not been found to be restrictive. Additionally, establishing a normative
22 reference value for strain in clinical practice remains unclear and is dependent on
23 specific clinical contexts ²⁷.

24 Data collection and analysis were conducted by a single observer, which
25 could potentially induce analysis bias. To minimize this possibility, images were

1 recorded and saved without patient identification or group affiliation. Intra- and
2 inter-observer analyses were performed at least 60 days after the initial image
3 acquisition, and no significant differences were observed in both analyses.

4 While additional evaluation with cardiac magnetic resonance (CMR),
5 scintigraphy, or laboratory exams could enhance identification of myocardial
6 amyloid infiltration and diagnosis of cardiac amyloidosis, these measures were
7 not included in the present study. Although CMR is diagnostically valuable, it
8 carries risks such as allergic reactions to contrast agents, challenges for patients
9 with claustrophobia, and its relatively high cost and invasive nature. Similarly,
10 scintigraphy, though effective for detecting amyloid deposits, also involves
11 exposure to radiation and may not be accessible in all clinical settings due to its
12 cost and the need for specialized equipment.

13 It is notable that most patients in this study had echocardiographic values
14 within normal limits, although significant differences compared to the control
15 group were observed, and patients had no cardiovascular symptoms. Long-term
16 follow-up with clinical and echocardiographic data could provide further insights
17 into the implications of these findings over time.

18 **Conclusion**

19 Our study demonstrated that the GLS and GCS of the left ventricle in
20 carriers of the transthyretin variant with preserved ejection fraction and a positive
21 family history for ATTR-CA were lower compared to the control group. Among the
22 clinical and echocardiographic variables evaluated, GLS and the mean E/e' ratio
23 were independent predictors of positive genetic testing for transthyretin
24 amyloidosis.

1

2 References

1. Gertz M, Adams D, Ando Y, Beirão JM, Bokhari S, Coelho T, et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. *BMC Fam Pract* [Internet]. 2020;21(1):198. Available from: <http://dx.doi.org/10.1186/s12875-020-01252-4>
2. Lioncino M, Monda E, Palmiero G, Caiazza M, Vetrano E, Rubino M, et al. Cardiovascular involvement in transthyretin cardiac amyloidosis. *Heart Fail Clin* [Internet]. 2022;18(1):73–87. Available from: <http://dx.doi.org/10.1016/j.hfc.2021.07.006>
3. Nagano N, Muranaka A, Nishikawa R, Ohwada W, Kouzu H, Kamiyama N, et al. Early detection of cardiac amyloidosis in transthyretin mutation carriers. *International Heart Journal* [Internet]. 2022 Jan 29;63(1):168–75. Available from: <https://doi.org/10.1536/ihj.21-336>
4. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. *Circulation* [Internet]. 2012;126(10):1286–300. Available from: <http://dx.doi.org/10.1161/CIRCULATIONAHA.111.078915>
5. Schmidt HH-J, Barroso F, González-Duarte A, Conceição I, Obici L, Keohane D, et al. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy: TTR-FAP Gene Carriers. *Muscle Nerve* [Internet]. 2016;54(3):353–60. Available from: <http://dx.doi.org/10.1002/mus.25210>
6. Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M. Diagnostic imaging of cardiac amyloidosis. *Nat Rev Cardiol* [Internet]. 2020;17(7):413–26. Available from: <http://dx.doi.org/10.1038/s41569-020-0334-7>
7. Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. *JACC Cardiovasc Imaging* [Internet]. 2019;12(5):823–33. Available from: <http://dx.doi.org/10.1016/j.jcmg.2018.02.016>
8. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types: Disease profiles and clinical courses of the 3 main types. *Circulation* [Internet]. 2009;120(13):1203–12. Available from: <http://dx.doi.org/10.1161/CIRCULATIONAHA.108.843334>
9. Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of

cardiac amyloidosis. *Heart* [Internet]. 2012;98(19):1442–8. Available from: <http://dx.doi.org/10.1136/heartjnl-2012-302353>

10. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* [Internet]. 2015;17(5):405–24. Available from: <http://dx.doi.org/10.1038/gim.2015.30>
11. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* [Internet]. 2015;16(3):233–70. Available from: <http://dx.doi.org/10.1093/ehjci/jev014>
12. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American society of echocardiography and the European association of cardiovascular imaging. *Eur Heart J Cardiovasc Imaging* [Internet]. 2016;17(12):1321–60. Available from: <http://dx.doi.org/10.1093/ehjci/jew082>
13. Mada RO, Lysyansky P, Daraban AM, Duchenne J, Voigt J-U. How to define end-diastole and end-systole?: Impact of timing on strain measurements. *JACC Cardiovasc Imaging* [Internet]. 2015;8(2):148–57. Available from: <http://dx.doi.org/10.1016/j.jcmg.2014.10.010>
14. Voigt J-U, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *Eur Heart J Cardiovasc Imaging* [Internet]. 2015;16(1):1–11. Available from: <http://dx.doi.org/10.1093/ehjci/jeu184>
15. Badano LP, Koliass TJ, Muraru D, Abraham TP, Aurigemma G, Edvardsen T, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *Eur Heart J Cardiovasc Imaging* [Internet]. 2018;19(6):591–600. Available from: <http://dx.doi.org/10.1093/ehjci/jev042>
16. Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: A head-to-head comparison of deformation and nondeformation parameters. *Circulation Cardiovascular Imaging* [Internet]. 2017 Mar 1;10(3). Available from: <http://dx.doi.org/10.1161/CIRCIMAGING.116.005588>


17. Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Störk S, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. *Circ Cardiovasc Imaging* [Internet]. 2013;6(6):1066–72. Available from: <http://dx.doi.org/10.1161/CIRCIMAGING.113.000683>
18. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation* [Internet]. 2016;133(24):2404–12. Available from: <http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021612>
19. Gopal DM, Ruberg FL, Siddiqi OK. Impact of genetic testing in transthyretin (ATTR) cardiac amyloidosis. *Curr Heart Fail Rep* [Internet]. 2019;16(5):180–8. Available from: <http://dx.doi.org/10.1007/s11897-019-00436-z>
20. Pagourelias ED, Duchenne J, Mirea O, Vovas G, Van Cleemput J, Delforge M, et al. The relation of ejection fraction and global longitudinal strain in amyloidosis: Implications for differential diagnosis. *JACC Cardiovasc Imaging* [Internet]. 2016;9(11):1358–9. Available from: <http://dx.doi.org/10.1016/j.jcmg.2015.11.013>
21. Cotella J, Randazzo M, Maurer MS, Helmke S, Scherrer-Crosbie M, Soltani M, et al. Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic study. *European Heart Journal - Cardiovascular Imaging* [Internet]. 2024 May 31 [cited 2024 Aug 9];25(6):754–61. Available from: <https://academic.oup.com/ehjcmg/article/25/6/754/7577731>
22. Ichimata S, Hata Y, Hirono K, Yamaguchi Y, Nishida N. Clinicopathological features of clinically undiagnosed sporadic transthyretin cardiac amyloidosis: a forensic autopsy-based series. *Amyloid* [Internet]. 2021;28(2):125–33. Available from: <http://dx.doi.org/10.1080/13506129.2021.1882979>
23. Aimo A, Tomasoni D, Porcari A, Vergaro G, Castiglione V, Passino C, et al. Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis. *Eur J Heart Fail* [Internet]. 2023;25(4):510–4. Available from: <http://dx.doi.org/10.1002/ejhf.2824>
24. Fine NM, White JA, Jimenez-Zepeda V, Howlett JG. Determinants and prognostic significance of serial right heart function changes in patients with cardiac amyloidosis. *Can J Cardiol* [Internet]. 2020;36(3):432–40. Available from: <http://dx.doi.org/10.1016/j.cjca.2020.01.020>
25. Chuy KL, Drill E, Yang JC, Landau H, Hassoun H, Nahhas O, et al. Incremental value of global longitudinal strain for predicting survival in patients with advanced AL amyloidosis. *JACC Cardio Oncology* [Internet]. 2020 Jun 1;2(2):223–31. Available from: <https://doi.org/10.1016/j.jacc.2020.05.012>
26. Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with

polyneuropathy. J Neurol [Internet]. 2021;268(6):2109–22. Available from: <http://dx.doi.org/10.1007/s00415-019-09688-0>

27. Yingchoncharoen T, Agarwal S, Popović ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr [Internet]. 2013;26(2):185–91. Available from: <http://dx.doi.org/10.1016/j.echo.2012.10.008>

1

1



2
3

Figure 1 Population of the Study.

1

2 **Table 1 Main Clinical Characteristics**

Variable	Control (n = 34)	TTR+ (n = 31)	p-value
Male sex, n	19 (55.9%)	13 (41.9%)	0.261 ^a
Age, years	37 (27; 41)	40 (29; 57)	0.090 ^b
Weight, kg	73 ± 13	74 ± 19	0.838 ^c
Height, cm	171 ± 8	169 ± 9	0.291 ^c
BSA, m ²	1.8 ± 0.2	1.8 ± 0.2	0.609 ^c
BMI, kg/m ²	25 ± 3	26 ± 5	0.423 ^c
Obesity	14 (41.2%)	16 (51.6%)	0.255 ^d
Overweight	11 (32.4%)	9 (29.0%)	
Obesity Grade I	3 (8.8%)	5 (16.1%)	
Obesity Grade II	0 (0%)	2 (6.5%)	
Systolic BP, mm Hg	110 (100; 120)	110 (110; 120)	0.565 ^b
Diastolic BP, mm Hg	70 (60; 70)	80 (60; 80)	0.184 ^b
Clinical history of hypertension	3 (8.8%)	2 (6.5%)	>0.999 ^e
Symptoms	-	14 (45.2%)	<0.001^a
Polyneuropathy	-	9 (29.0%)	
Intestinal dysautonomia	-	3 (9.6%)	
Dysautonomia	-	1 (3.2%)	
Carpal tunnel syndrome	-	1 (3.2%)	

3 P-values < 0.05 are show in bold. Variables are presented as mean ± SD, median (IQR), or percentile (%).
 4 a: Chi-square, b: Mann-Whitney, c: Student's t-test, d: Fisher's exact, e: Likelihood ratio.
 5 Abbreviation: BMI: Body Mass Index; BP: Blood pressure; BSA: Body Surface Area.

6

1 **Table 2 Echocardiographic Parameters**

Variable	Control (n = 34)	TTR+ (n = 31)	p-value
LVIDd, mm	47 (43; 50)	46 (43; 49)	0.395 ^b
LVISd, mm	28 (26; 30)	28 (27; 30)	0.356 ^b
IVSd, mm	8 (7; 9)	10 (8; 11)	0.001^b
PWd, mm	8 (7; 9)	9 (8; 10)	0.001^b
LVM, g	130 ± 34	156 ± 42	0.008^c
LVMi (g/m ²)	69 ± 14	84 ± 16	<0.001^c
RWT	0.35 ± 0.04	0.41 ± 0.06	<0.001^c
LV geometry			<0.001^a
Con-R	2 (5.8%)	8 (25.8%)	
Con-H	0 (0%)	4 (12.9%)	
Ecc-H	0 (0%)	1 (3.2%)	
LVEF Simpson (%)	66 (61; 70)	63 (61; 68)	0.185 ^b
LV Volume Diastole (mL / m ²)	63 (47; 79)	67 (48; 86)	0.400 ^b
LV Volume Systole (mL / m ²)	21 (15; 28)	27 (23; 35)	0.001^b
LA diameter, mm	34 ± 3	34 ± 5	0.656 ^c
LA volume index, ml/m ²	23 (15; 32)	24 (14; 43)	0.192 ^b
E-wave, cm/s	80 ± 17	85 ± 19	0.314 ^c
A-wave, cm/s	50 (46; 62)	63 (54; 84)	<0.001^b
E/A ratio	1.6 ± 0.5	1.3 ± 0.4	0.010 ^c
DT, ms	159 ± 28	177 ± 34	0.027 ^c
E/e'	6 (5; 7)	7 (7; 10)	0.001^b
e' septum, cm/s	12 (10; 13)	9 (7; 12)	0.003^b
e' lateral, cm/s	15 (13; 19)	13 (10; 15)	0.029^b
RA area, cm ²	14 (13; 15)	14 (12; 15)	0.420 ^b
RVIDd mid, mm	29 (26; 30)	28 (25; 31)	0.711 ^b
RV FAC, %	49 (40; 54)	51 (45; 53)	0.392 ^b
TAPSE, mm	24 (21; 26)	22 (20; 25)	0.115 ^b
RV s', cm/s	12 (11; 13)	12 (11; 14)	0.223 ^b
IVC, mm	13 (12; 15)	13 (12; 14)	0.626 ^b
TR Vmax, m/s	1.9 (1.5; 2.6)	2 (1.7; 2.9)	0.188 ^b
PSAP, mmHg	21 (14; 32)	22 (16; 39)	0.065 ^b
Diastole Function 1			0.224 ^d
Normal	34 (100%)	29 (93.5%)	
Indeterminate	0 (0%)	2 (6.5%)	
Diastole Function 2			0.007^a
Type I Dysfunction	2 (59%)	12 (38.4%)	
Type III Dysfunction	0 (0%)	1 (3.2%)	

2 P-values < 0.05 are show in bold. Data are expressed as mean ± SD or median (IQR).

3 a: Chi-square, b: Mann-Whitney, c: Student's t-test, d: Fisher's exact.

4 Abbreviation: A-wave, late wave velocity of mitral diastolic inflow; Con-H, concentric hypertrophy; Con-
5 R, concentric remodeling; Ecc-H, eccentric hypertrophy; DT, deceleration time; E-wave, initial diastolic
6 velocity of mitral inflow; E/e', mitral annular velocity by tissue Doppler; IVC, inferior vena cava; IVSd,
7 interventricular septum thickness at end-diastole; LVIDd, left ventricular internal diastolic diameter at end-
8 diastole; LVISd, left ventricular internal systolic diameter at end-diastole; LVEF, left ventricular ejection
9 fraction; LVMi, left ventricular mass indexed; PSAP, pulmonary systolic arterial pressure; PWd, posterior
10 wall thickness at end-diastole; RA, right atrial; RVIDd, right ventricular internal diameter at end-diastole;
11 FAC, fractional area change; RWT, relative wall thickness; s', tissue Doppler of the tricuspid ring; TAPSE,
12 tricuspid annular plane systolic excursion; TR Vmax, maximum velocity of tricuspid regurgitation jet.

1 **Table 3 Myocardial Strain Parameters**

Variable	Control (n = 34)	TTR+ (n = 31)	p-value
GCS*, %	-28 ± 4	-21 ± 4	<0.001^c
CS basal*, %	-26 ± 5	-18 ± 4	<0.001^c
CS medium*, %	-27 ± 5	-20 ± 4	<0.001^c
CS apical*, %	-31 ± 6	-24 ± 6	<0.001^c
GLS, %	-25 (-26; -23)	-19 (-20; -17)	<0.001^b
LS basal, %	-22 ± 3	-17 ± 3	<0.001^c
LS medium, %	-24 ± 3	-18 ± 3	<0.001^c
LS apical, %	-27 ± 4	-23 ± 4	<0.001^c
4C, %	-24 (-26; -21)	-19 (-21; -17)	<0.001^b
2C, %	-24 (-26; -22)	-19 (-22; -17)	<0.001^b
3C, %	-24 (-27; -23)	-19 (-21; -17)	<0.001^b
RV GLS, %	-25 ± 5 (n=11)	-18 ± 4 (n=11)	0.005^c
RV FW GLS, %	-24 ± 4 (n=11)	-18 ± 4 (n=11)	<0.001^c
RELAPS	0.58 ± 0.08	0.66 ± 0.08	<0.001^c
SAB	1.4 ± 0.3	1.7 ± 0.3	<0.001^c

2 P-values < 0.05 are show in bold. Data are expressed as mean ± SD or median (IQR).


3 b: Mann-Whitney, c: Student's t-test.

4 Abbreviation: 4C: four-chambers; 2C: two-chambers; 3C: three-chambers; CS: circumferential strain; FW: free wall; GCS: global circumferential strain; GLS: global longitudinal strain.

5 *One case was excluded from the analysis due to circumferential strain reading limitation.

6

1



2

3

Figure 2 Strain values in TTR+ and control groups.


4

LS, longitudinal strain; CS, circumferential strain; GLS. Global longitudinal strain; GCS,

5

global circumferential strain.

1



2

3 **Figure 3** ROC analysis showed global longitudinal strain and E/e' ratio to distinguish
4 TTR+ carriers.